undamentalytics Newsletter
Sign in

Arrivent Biopharma, Inc. (AVBP) stock

Add to watchlist

Add holding +

NASDAQ: AVBP Nasdaq Biotechnology Next results ~November 16, 2026

Arrivent Biopharma, Inc. is a US-listed company in the biotechnology industry. Its financial year ends in December.

Who’s trading

What company insiders, investment funds and members of Congress have been doing with the stock, from their own filings.

  • Insiders0 buying, 1 selling0 purchases and 1 sale by directors and officers, last 12 monthsInsider trades
  • Funds104 adding, 45 cuttingOf 31 active managers that changed their stake, 19 added; quarter to June 30, 2026Fund buyers and sellers

The Fundamentalytics view

Next results ~November 16, 2026 (estimated)

Current signal Share count rising (dilution): Diluted shares outstanding rose 30.4% year over year.

Assembled from SEC-filed figures — the full workings are on this page and in our methodology. Observations, not recommendations.

Highlights

How we pick these

Strengths

Nothing in Arrivent Biopharma, Inc.'s latest figures clears our strength thresholds.

Things to watch

  • Results due soon. Results are expected around 9 November; the share price can move sharply on the day.
  • Share dilution. Diluted shares rose 30.4% in a year.
  • Volatile shares. Over the past year the shares showed annualised volatility of 80% and a beta of 0.9 against the S&P 500.
  • Insiders selling. 1 insiders sold $13M of stock over the past 365 days and none bought (0% under pre-set trading plans).
  • Heavily shorted. 14.6% of the shares available to trade are sold short (3.6 days of average volume to cover).
  • Missing expectations. Earnings per share fell short of the consensus estimate in 3 of the last four quarters.

Latest results

Earnings per share
-$1.05 against an average estimate of -$0.98: missed by 6.7%
Share reaction
-4.4% in the first session after the results on August 12, 2026, against +0.9% for the S&P 500
Next report
November 16, 2026; average EPS estimate -$1.06

Arrivent Biopharma's figures from its SEC filings and results release; estimates are the analysts' average. Not a recommendation.

Price chart

  • 1 day-10.2%
  • 1 week-13.1%
  • 1 month-52.8%
  • This year-33.6%
  • 1 year-28.7%
  • S&P 500 this year+11.2%

Closing prices to 2026-11-02. Price change only, dividends excluded.

Loading chart…

Third-party market data · may be delayed

At a glance

Trailing twelve months, from SEC filings

Profitability

EPS (TTM, diluted)
$-3.69

Growth

Share count change
+30.4%

Earnings

Last results
August 12, 2026
Next results (est.)
November 9, 2026

News & updates

Updated October 31, 2026

Company announcements, filed results and changes that matter to shareholders.

  1. Announcement
  2. Announcement
  3. Announcement
  4. Announcement
  5. Results

Refreshed hourly when new source data is available. Summaries are checked against company releases and SEC filings. Company announcement headlines are labelled when a checked summary is unavailable.

Valuation

Arrivent Biopharma, Inc. valuation models and calculator

No model value for Arrivent Biopharma, Inc. at the moment. Current status: limited reported history: available models are shown without a Buy/Hold/Sell rating. Available reported financials are shown below.

Fundamentalytics rating

model v1.6 · 2026-11-03

Not rated: limited reported history: available models are shown without a Buy/Hold/Sell rating.

The inputs used by the models below have passed source checks. Individual model values are available below and in the interactive valuator. Their differences are shown explicitly; the platform combined value and recommendation remain withheld.

Valuation models

We value Arrivent Biopharma, Inc. as an operating company, with every model that fits that kind of business. Cost of equity 9.4%: the 10-year Treasury yield (4.9%) plus a beta of 0.99 times a 4.5% equity risk premium.

Value per share by model
Model Value per share In the combined value?
Price-to-earnings vs peers Earnings per share times peers' typical (harmonic-mean) price-to-earnings. — Does not apply: This model is withheld pending its input or assumption review.
Residual income Book value plus the present value of returns above the cost of equity, fading over ten years. — Does not apply: This model is withheld pending its input or assumption review.
Justified price-to-book Book value times (return on equity - growth) / (cost of equity - growth): steady-state returns. — Does not apply: This model is withheld pending its input or assumption review.
Revenue-to-maturity model Revenue grown to maturity with the cash margin moving to the industry's; for companies not yet profitable. — Does not apply: This model is withheld pending its input or assumption review.
Forward price-to-sales vs peers Next year's consensus sales per share times peers' typical forward price-to-sales; only when earnings are negative. Uses analysts' consensus estimates (third-party data), not our forecasts. ~$0.4 ~$0.4–$1.5 Left out: out of range vs price (0.03x)
Combined value Individual source-checked model scenarios are available. The platform combined value and recommendation remain withheld. — Combined value withheld. Review the individual models and their assumptions.

Different models fail in different ways, so where several apply we average them rather than trust one. Peer-based models compare Arrivent Biopharma, Inc. with Biotechnology in our coverage, using third-party market data. Model values are estimates under stated assumptions, updated as new filings arrive; not price targets or investment advice. How each model works.

Moat

Not assessed: fewer than five years of comparable figures in the filings. AI disruption exposure for this industry: Medium.

A rules-based reading of reported figures, not a forecast and not investment advice. How the score is built: methodology.

Forecasts and guidance

Next results: November 16, 2026, after the close. Analysts expect revenue of $0 and EPS of −$1.06 (range −$1.22 to −$1.00) for the quarter.

Analysts' consensus

Fiscal yearEPSGrowthRevenueGrowth
Current −$4.20 +3% — 0%
Next −$3.72 +11% $6m 0%

How the EPS forecast has moved

The consensus EPS forecast for the current fiscal year is +2.8% on 90 days ago. In the last 30 days, 3 analysts raised Arrivent Biopharma, Inc.'s forecast and 0 cut it.

Consensus EPS forecast Arrivent Biopharma, Inc., last 90 days
−$6.00 −$4.00 −$2.00 $0.00 90 days ago 60 days ago 30 days ago 7 days ago Now Current fiscal year, 90 days ago: −$4.09 Current fiscal year, 60 days ago: −$4.34 Current fiscal year, 30 days ago: −$4.32 Current fiscal year, 7 days ago: −$4.21 Current fiscal year, Now: −$4.20 −$4.20 Next fiscal year, 90 days ago: −$3.48 Next fiscal year, 60 days ago: −$3.81 Next fiscal year, 30 days ago: −$3.93 Next fiscal year, 7 days ago: −$3.72 Next fiscal year, Now: −$3.72 −$3.72

Average of analysts' published estimates (third-party data).

View chart data
Period Current fiscal yearNext fiscal year
90 days ago −$4.09−$3.48
60 days ago −$4.34−$3.81
30 days ago −$4.32−$3.93
7 days ago −$4.21−$3.72
Now −$4.20−$3.72

Earnings against estimates

Quarter toEstimateActualSurprise
Jun 2026 −$0.98 −$1.05 −6.7%
Mar 2026 −$0.89 −$0.96 −7.4%
Dec 2025 −$0.85 −$0.78 +7.7%
Sept 2025 −$0.78 −$0.83 −6.0%

Adjusted EPS as companies report it, against the average analyst estimate.

Analyst recommendations

11 analysts, Oct 2026
Buy11100%
Hold00%
Sell00%

Monthly trend

  1. Oct 20261111
  2. Sep 20261111
  3. Aug 20261111
  4. Jul 20261111

Counts of recommendations published by analysts covering Arrivent Biopharma, Inc., by month. Source: Aggregated broker recommendations (third-party data). Aggregated counts only: we do not reproduce any firm's recommendation or price target, and these are not Fundamentalytics ratings.

Positioning

Short interest
14.6%
of tradable shares
Days to cover
3.56
at average volume
Short interest, 1 month
−22%
to October 15, 2026
Held by institutions
—
of shares
Held by insiders
1.5%
of shares
Employees
77
full time

Consensus figures average analysts' published estimates (third-party data); guidance is the company's own. Neither is our forecast. Short interest is reported twice a month and lags. Market data may be delayed.

This section is general information, not investment advice or a personal recommendation, and it does not take account of your objectives or circumstances. Forecasts and guidance are estimates, not promises: companies miss their own guidance and analysts' figures are often revised. Prices can fall as well as rise, and you can lose money. See our disclaimer.

Share-price performance

Market data may be delayed

Return and risk by year

Calendar year 20252026 to date
Return
AVBP−25%−34%
Industry peers (median)−5%−26%
S&P 500+18%+11%
Months that ended higher
AVBP42%64%
S&P 50075%46%
Largest fall from a high during the year
AVBP−44%−62%
S&P 500−19%−9%

Worst fall since January 26, 2024: 63% from November 7, 2024 to November 2, 2026. Getting back needed a 167% gain, and the shares have not yet recovered.

Price behaviour

52-week range
$13.35 – $34.74
From 52-week high
−61.6%
vs 50-day average
−45.4%
vs 200-day average
−50.4%
Volatility (1 year)
80%
Beta vs S&P 500
0.91

Volatility is the annualised standard deviation of daily returns. Beta 1.5 means the shares typically moved 1.5% for each 1% move in the S&P 500 over the past year. Prices to November 2, 2026.

Share price after results

Next day
4 up, 7 down
typical move ±6.1%
After a week
5 up, 6 down
typical move ±8.3%
After a month
6 up, 5 down
typical move ±12.0%
Results releasedNext dayS&P 500 next day5 days21 days
August 12, 2026 −4.4% +0.9% −4.4% −7.6%
May 11, 2026 −1.8% +0.1% −8.3% +3.4%
March 5, 2026 −11.8% −1.9% −9.3% −6.0%
November 10, 2025 +7.4% +1.8% +14.7% +34.9%
August 11, 2025 −5.8% +0.9% +6.9% +4.9%
May 12, 2025 −5.2% +4.0% −4.0% +15.6%
March 3, 2025 −7.0% −2.9% −8.0% −23.6%
November 14, 2024 −14.6% −1.9% −16.5% −16.9%
August 14, 2024 +3.2% +2.0% +3.5% +2.8%
May 8, 2024 +4.3% +0.6% +13.0% +7.5%
March 28, 2024 +1.7% −0.2% +2.5% −9.2%

From the close before the release date to the close 1, 5 and 21 trading days after it, so releases before the open and after the close are both captured. Past moves don't predict future ones.

Fundamentals

Data: SEC EDGAR XBRL company facts (as filed in 10-K/10-Q); forms 10-K, 10-Q. Generated November 3, 2026. Definitions in our methodology.

Dividends, buybacks and capital spending

Diluted share count
+30.4%
year over year

Who owns it

Funds buying and selling
Reported value
$1.6B
Institutions reporting
157
Shares held vs prior quarter
▲ 9.6%
Positions opened / closed
33 / 15

Top buyers and sellers, Q2 2026: 104 institutions bought and 45 sold ; the biggest buyer was Vivo Capital, LLC (+796K shares) and the biggest seller Fund 1 Investments, LLC (−500K). See which funds bought and sold →

Largest reported holders, June 30, 2026
Manager Value Shares Share of 13F value Shares QoQ
Montanova Capital, LLC $157M 4.5M 9.8% ▲ 2.6%
Infinitum Asset Management, LLC $154M 4.4M 9.6% ▲ 7.0%
Hhlr Advisors, Ltd. $136M 3.9M 8.5% 0.0%
Blackrock, Inc. $113M 3.3M 7.0% ▲ 28.5%
Orbimed Advisors LLC $105M 3.0M 6.6% 0.0%
FMR LLC $96.5M 2.8M 6.0% ▼ 7.9%
Octagon Capital Advisors LP $68.5M 2.0M 4.3% 0.0%
Vanguard Capital Management LLC $61.7M 1.8M 3.8% ▲ 16.1%
Sofinnova Investments, Inc. $58.9M 1.7M 3.7% 0.0%
State Street Corp $58.8M 1.7M 3.7% ▲ 19.1%
Vivo Capital, LLC $58.4M 1.7M 3.6% ▲ 89.9%
Novo Holdings A/S $52.1M 1.5M 3.3% ▼ 22.8%

From Form 13F filings with the SEC ( quarterly data sets), as reported by each manager for June 30, 2026 and filed up to 45 days later. 13F reports cover long US-listed positions of managers above $100M only, so this is not Arrivent Biopharma, Inc.'s complete shareholder register. Values are as reported by the filers .

Insider trading activity

Full insider history and chart
Insider purchases History → $0 0 trades by 0 insiders, last 12 months Insider sales History → $13M 1 trade by 1 insider · 0% under pre-set plans
Net ▼ $13M net selling
Insider Date Trade Shares Price Value
Hhlr Advisors, Ltd. 10% owner December 10, 2025 Sell 555,555 $23.37 $13M

From insiders' Form 4 filings with the SEC. Excludes awards, option exercises and shares withheld for tax. "Pre-set plan" means the filing marks the trade as made under a Rule 10b5-1 plan. See every insider trade since five years ago, on a price chart.

Earnings dates and SEC filings

Results announcements

Next expected around November 9, 2026 estimated from the company's past filing pattern, not announced

  • August 12, 2026
  • May 11, 2026
  • March 5, 2026
  • November 10, 2025
  • August 11, 2025
  • May 12, 2025

Recent SEC filings

Data status

When each part of this page on Arrivent Biopharma, Inc. was last updated.

DataLast updatedSource
Share priceExchange closing prices
News and updatesCompany releases and SEC 8-K filings
Analyst estimatesAggregated analyst estimates
Valuation and scoresOur models, from the filed figures

How we build and check these figures: methodology and data sources.

Arrivent Biopharma, Inc. in brief

What does Arrivent Biopharma, Inc. do?
Arrivent Biopharma, Inc. is a US-listed company in the biotechnology industry. Its financial year ends in December.
What is Arrivent Biopharma, Inc.'s stock ticker?
Arrivent Biopharma, Inc. trades under the ticker AVBP on Nasdaq. This page brings together its financial statements, valuation models, ownership and recent company updates.
Who are Arrivent Biopharma, Inc.'s largest institutional shareholders?
By value reported in 13F filings for June 30, 2026, the largest reported holders are Montanova Capital, LLC, Infinitum Asset Management, LLC and Hhlr Advisors, Ltd. 13F reports cover long US-listed positions of managers above $100M, filed up to 45 days after quarter end.
Are insiders buying or selling Arrivent Biopharma, Inc. stock?
Over the last 12 months, Arrivent Biopharma, Inc.'s directors and officers reported 0 open-market purchases and 1 sales on Form 4. The insider trading page charts every trade.
When is Arrivent Biopharma, Inc.'s next earnings date?
Around November 16, 2026, estimated from the spacing of its past results announcements (8-K filings). That is an estimate, not a confirmed date — Arrivent Biopharma, Inc. announces its own schedule.